Tailoring Bruton Tyrosine Kinase Inhibitor Strategies for CLL: Managing Today, Anticipating Tomorrow Keeping Current
-
- Medicine
Are you selecting the right Bruton tyrosine kinase (BTK) inhibitor for your patients with chronic lymphocytic leukemia (CLL)? Experts discuss the key differentiators and upcoming developments in the field.
Credit available for this activity expires: 04/26/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000717?ecd=bdc_podcast_libsyn_mscpedu
Are you selecting the right Bruton tyrosine kinase (BTK) inhibitor for your patients with chronic lymphocytic leukemia (CLL)? Experts discuss the key differentiators and upcoming developments in the field.
Credit available for this activity expires: 04/26/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000717?ecd=bdc_podcast_libsyn_mscpedu
37 min